Of note, the transition to HLA-DR+ neutrophils was accompanied by a shift toward the identified TAN signature (elevated expression of CD83 and LOX-1 and lower expression of CD181 [CXCR1], CD62L [SELL], and CD16) in neutrophils derived from NSCLC tumor tissue (Figure S6E). The gene discussed is SELL; the disease is non-small cell lung carcinoma.